Adial Pharmaceuticals Inc... (ADIL)
undefined
undefined%
At close: undefined
1.04
-4.58%
After-hours Jan 07, 2025, 05:09 PM EST

Company Description

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.

Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.

The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders.

Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Adial Pharmaceuticals Inc.
Adial Pharmaceuticals Inc. logo
Country United States
IPO Date Jul 27, 2018
Industry Biotechnology
Sector Healthcare
Employees 4
CEO Cary John Claiborne MBA

Contact Details

Address:
1180 Seminole Trail
Charlottesville, Virginia
United States
Website https://www.adialpharma.com

Stock Details

Ticker Symbol ADIL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001513525
CUSIP Number 00688A106
ISIN Number US00688A2050
Employer ID 80-0667150
SIC Code 2834

Key Executives

Name Position
Cary John Claiborne MBA Chief Executive Officer, President & Director
John R. Martin J.D. Chief Legal Officer
Joseph A. M. Truluck M.B.A., MBA Chief Financial Officer, Treasurer & Secretary
Andrew Taubman Vice President of Corporate Development
Catherine Fratila Controller

Latest SEC Filings

Date Type Title
Dec 31, 2024 424B3 Filing
Dec 20, 2024 S-1 Filing
Dec 18, 2024 8-K Current Report
Dec 12, 2024 S-8 Filing
Dec 06, 2024 8-K Current Report
Dec 05, 2024 4 Filing
Nov 18, 2024 8-K Current Report
Nov 18, 2024 4 Filing
Nov 18, 2024 3 Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...